

# Intarcia Therapeutics, Inc. Overview

One Marina Park Drive 13th Floor

Boston, MA 02210

<http://www.intarcia.com>

[Facebook](#)

[@intarcia](#)

[LinkedIn](#)

\$3,803,339,576 (08/03/2017)

Biotechnology

New England

Active Investment

Legal Counsel

Cooley LLP

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

SIC

2836 - Biological Products, Except Diagnostic Substance

CIK

1086688

FKA: PhaseGain Clinical Research, Inc. and FKA: BioMedicines, Inc. Intarcia Therapeutics, Inc. develops therapeutic drug delivery devices. The Company is a biopharmaceutical company developing therapies for the treatment outcome. It addresses diseases that require long-term chronic therapy by reducing the burden therapies often place on the patient's life. Intarcia stabilizes macromolecules and delivers them over an extended period of time via the DUROS drug delivery platform.

## [Key Management](#)

**James Ahlers**

CFO, COO

**Kurt Graves**

Chairman, CEO, President

**Owen Hughes**

Chief Business Officer, Head of Corporate Development

**Jay Smith**

Chief Experience Officer

**Raymond T Keane**

Chief Legal Officer

**Michelle Baron**

Chief Medical Officer

**Andrew Young**

Chief Scientific Officer

**Bryan E. Roberts**

Director

**Emad Rizk**

Director

**Gino Santini**

Director

**Glen Sato**

Director

**Irwin Scher**

Director

**Nancy Thornberry**

Director

**James P Brady**

VP, Human Resources